Please use the form below to order a Videoconference. After you complete the form, click the "Send" button. This information will be held in confidence. An FDALive representative will be in contact with you soon.
- Oncologic Drugs AdComm
Meeting Date: 7/9/15-7/9/15
The committee will discuss biologics license application 125547, necitumumab injection, application submitted by Eli Lilly and Company. The proposed indication (use) for this product is in combination with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer.
|Location:||FDA Meeting Room||Related News Links:||Not Available|